Last updated on February 2018

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck


Brief description of study

The main purpose of this study is to compare nivolumab and ipilimumab with the Extreme study regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer

Clinical Study Identifier: NCT02741570

Contact Investigators or Research Sites near you

Start Over

Site 0113

Local Institution
Fukuoka-shi, Japan
1.26miles
  Connect »